2
|
Scarinci E, Tropea A, Russo G, Notaristefano G, Messana C, Alesiani O, Fabozzi SM, Lanzone A, Apa R. Increased fibulin-1 plasma levels in polycystic ovary syndrome (PCOS) patients: possible contribution to the link between PCOS and cardiovascular risk. J Endocrinol Invest 2019; 42:91-96. [PMID: 29680975 DOI: 10.1007/s40618-018-0891-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Accepted: 04/14/2018] [Indexed: 12/22/2022]
Abstract
PURPOSE To investigate a possible relation between fibulin-1 plasma levels and PCOS. DESIGN ELISA quantitative determination of human fibulin-1. METHODS 50 women with PCOS and 40 control patients who attended the Unit of Human Reproductive Pathophysiology, Università Cattolica del Sacro Cuore, Rome, were enrolled. Ultrasonographic pelvic examinations, hormonal profile assays, oral tolerance test OGTT, lipid profile and ELISA quantitative determination of human fibulin-1 were performed. RESULTS Fibulin-1 levels were found to be statistically significantly higher in PCOS patients than in matched control women. No statistically significant positive correlation was found between fibulin-1 and AUCi, HOMA-IR, total cholesterol, LDL, AMH, androstenedione and FAI, whereas a statistically significant positive correlation was found between fibulin-1 and 17OHP (p = 0.016) in the PCOS group. However, multivariable linear regression analysis showed that 17 OH P did not independently predict fibulin-1 levels (p = 0.089). CONCLUSIONS Our data could contribute to explain the hypothesized increased cardiovascular risk and vascular damage in patients with PCOS. A better understanding of the cellular and molecular mechanisms involved in cardiometabolic disorders associated with PCOS is mandatory to identify new therapeutic strategies to eventually prevent the progression of cardiovascular diseases in these patients.
Collapse
Affiliation(s)
- E Scarinci
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy.
| | - A Tropea
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy
| | - G Russo
- Department of Cardiovascular Sciences, Università Cattolica del Sacro Cuore, Rome, Italy
| | - G Notaristefano
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy
| | - C Messana
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy
| | - O Alesiani
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy
| | - S M Fabozzi
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy
| | - A Lanzone
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy
| | - R Apa
- Department of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, L.go Agostino Gemelli, 8, 00168, Rome, Italy
| |
Collapse
|
5
|
Holmager P, Egstrup M, Gustafsson I, Schou M, Dahl JS, Rasmussen LM, Møller JE, Tuxen C, Faber J, Kistorp C. Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve. BMC Cardiovasc Disord 2017; 17:22. [PMID: 28068900 PMCID: PMC5223321 DOI: 10.1186/s12872-016-0437-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Accepted: 12/07/2016] [Indexed: 02/08/2023] Open
Abstract
Background Heart failure (HF) patients with diabetes (DM) have an adverse prognosis and reduced functional capacity, which could be associated with cardiac fibrosis, increased chamber stiffness and reduced left ventricular (LV) contractile reserve. Galectin-3 (Gal-3) and fibulin-1 are circulating biomarkers potentially reflecting cardiac fibrosis. We hypothesize that plasma levels of Gal-3 and fibulin-1 are elevated in HF patients with DM and are associated with reduced LV contractile reserve in these patients. Methods A total of 155 patients with HF with reduced ejection fraction underwent a low-dose dobutamine echocardiography and blood sampling for biomarker measurements. Patients were classified according to history of DM and an oral glucose tolerance test (OGTT) as: normal glucose tolerance (NGT) (n = 70), impaired glucose tolerance (IGT) (n = 25) and DM (n = 60). Results Galectin-3 levels were elevated in DM patients as compared to non-diabetic patients (P = 0.02), while higher fibulin-1 levels were observed in HF patients with IGF and DM (P = 0.07). Reduced LV contractile reserve was associated with increasing Gal-3 levels (β = −0.19, P = 0.03) although, this association was attenuated after adjustment for estimated glomerular filtration rate (P = 0.66). Fibulin-1 was not associated with LV contractile reserve (P = 0.71). Conclusions Galectin-3 and fibulin-1 levels were elevated in HF patients with impaired glucose metabolism. However, reduced LV contractile reserve among HF patients with DM does not to have an independent impact on plasma Gal-3 and fibulin-1 levels.
Collapse
Affiliation(s)
- Pernille Holmager
- Department of Medicine, Endocrine Unit, Herlev University Hospital, Herlev, Denmark. .,Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark. .,Department of Endocrinology, Herlev Hospital, Herlev, Denmark.
| | - Michael Egstrup
- Department of Cardiology, Rigshospitalet, Copenhagen, Denmark
| | - Ida Gustafsson
- Department of Cardiology, Hvidovre University Hospital, Hvidovre, Denmark
| | - Morten Schou
- Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark.,Department of Cardiology, Herlev University Hospital, Herlev, Denmark
| | - Jordi S Dahl
- Department of Cardiology and Cardiothoracic Surgery, Odense University Hospital, Odense, Denmark
| | - Lars Melholt Rasmussen
- Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark.,Centre of Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark
| | - Jacob E Møller
- Department of Cardiology, Odense University Hospital, Odense, Denmark
| | - Christian Tuxen
- Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
| | - Jens Faber
- Department of Medicine, Endocrine Unit, Herlev University Hospital, Herlev, Denmark.,Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
| | - Caroline Kistorp
- Department of Medicine, Endocrine Unit, Herlev University Hospital, Herlev, Denmark.,Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark
| |
Collapse
|
7
|
Preil SAR, Kristensen LP, Beck HC, Jensen PS, Nielsen PS, Steiniche T, Bjørling-Poulsen M, Larsen MR, Hansen ML, Rasmussen LM. Quantitative Proteome Analysis Reveals Increased Content of Basement Membrane Proteins in Arteries From Patients With Type 2 Diabetes Mellitus and Lower Levels Among Metformin Users. ACTA ACUST UNITED AC 2015; 8:727-35. [PMID: 26371159 DOI: 10.1161/circgenetics.115.001165] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2014] [Accepted: 08/25/2015] [Indexed: 01/13/2023]
Abstract
BACKGROUND The increased risk of cardiovascular diseases in type 2 diabetes mellitus has been extensively documented, but the origins of the association remain largely unknown. We sought to determine changes in protein expressions in arterial tissue from patients with type 2 diabetes mellitus and moreover hypothesized that metformin intake influences the protein composition. METHODS AND RESULTS We analyzed nonatherosclerotic repair arteries gathered at coronary bypass operations from 30 patients with type 2 diabetes mellitus and from 30 age- and sex-matched nondiabetic individuals. Quantitative proteome analysis was performed by isobaric tag for relative and absolute quantitation-labeling and liquid chromatography-mass spectrometry, tandem mass spectrometry analysis on individual arterial samples. The amounts of the basement membrane components, α1-type IV collagen and α2-type IV collagen, γ1-laminin and β2-laminin, were significantly increased in patients with diabetes mellitus. Moreover, the expressions of basement membrane components and other vascular proteins were significantly lower among metformin users when compared with nonusers. Patients treated with or without metformin had similar levels of hemoglobin A1c, cholesterol, and blood pressure. In addition, quantitative histomorphometry showed increased area fractions of collagen-stainable material in tunica intima and media among patients with diabetes mellitus. CONCLUSIONS The distinct accumulation of arterial basement membrane proteins in type 2 diabetes mellitus discloses a similarity between the diabetic macroangiopathy and microangiopathy and suggests a molecular explanation behind the alterations in vascular remodeling, biomechanical properties, and aneurysm formation described in diabetes mellitus. The lower amounts of basement membrane components in metformin-treated individuals are compatible with the hypothesis of direct beneficial drug effects on the matrix composition in the vasculature.
Collapse
Affiliation(s)
- Simone A R Preil
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Lars P Kristensen
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Hans C Beck
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Pia S Jensen
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Patricia S Nielsen
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Torben Steiniche
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Marina Bjørling-Poulsen
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Martin R Larsen
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Maria L Hansen
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.)
| | - Lars M Rasmussen
- From the Department of Biochemistry and Pharmacology, Odense University Hospital (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Protein Research Group, Department of Biochemistry and Molecular Biology (M.R.L.), University of Southern Denmark, Odense, Denmark; Center for Individualized Medicine in Arterial Diseases (CIMA), Center for Clinical Proteomics (CCP), Odense Patient Explorative Network (OPEN) (S.A.R.P., L.P.K., H.C.B., P.S.J., M.B.-P., M.L.H., L.M.R.) and Department of Cardiothoracic and Vascular Surgery (M.L.H.), Odense University Hospital, Odense, Denmark; and Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark (P.S.N., T.S.).
| |
Collapse
|